Melatonin Receptor Signaling in Human Pathologies: From Molecular Mechanisms to Therapeutic Targets
Clicks: 1
ID: 313382
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #49 of 53 articles by views in Food & function
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The Melatonin Receptor 1A (MTNR1A), a highly conserved G protein-coupled receptor (GPCR), mediates crucial physiological functions. Its structure features an N-terminus responsible for melatonin binding and a C-terminus that initiates downstream signaling pathways to modulate target gene expression. Given MTNR1A's ability to form homodimers or heterodimers with other GPCRs, its expression levels are critical for the precise control of cellular signaling. This review article provides a comprehensive update on MTNR1A, highlighting recent developments concerning its expression distribution, gene regulation, protein motifs, and mediated signaling pathways. We also discuss the clinical relevance of single nucleotide polymorphisms (SNPs) associated with the MTNR1A receptor and the range of diseases linked to its dysfunction. Current understanding and future perspectives regarding the gene regulation and stimulation of MTNR1A expression are critically addressed. Furthermore, we investigate the role of MTNR1A genetic variants in idiopathic osteoporosis and the association between decreased MTNR1A expression and membranous nephropathy. The systemic involvement of MTNR1A downregulation in cancer, fetal growth restriction, type 2 diabetes, and Parkinson's and Alzheimer's diseases is further underlined by its established biological functions. In conclusion, targeting MTNR1A-related downregulation and developing specific agonists or modulators offers a promising avenue for advancement in therapeutic medicine.
| Reference Key |
openalex_W7161277268
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yen‐Sung Huang, Sheng-Ding Wu, Hsi-Chih Chen, Kuo‐Cheng Lu, Shuk‐Man Ka, Chia‐Chao Wu |
| Journal | Food & function |
| Year | 2026 |
| DOI |
10.1152/function.011.2026
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.